Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PIEZO-101
- Development stage
- Phase 1
- Lead developer
- Piezo Therapeutics
- Modality
- Gene Therapies
- Administration
- Intradermal
01
Overview
PIEZO-101 is an investigational plasmid DNA-based gene therapy developed by Piezo Therapeutics for the treatment of skin aging and extracellular matrix rejuvenation. It is designed as a biostimulator that restores the expression of key structural proteins within the skin to improve integrity and elasticity. The drug is administered via intradermal injection followed by localized electroporation using the proprietary Piezopen device, which facilitates the cellular uptake of the DNA plasmid. PIEZO-101 is currently being evaluated in a Phase 1 first-in-human clinical trial to assess its safety, tolerability, and pharmacodynamic effects in healthy adult female participants.
Beyond the preview
Go deeper on PIEZO-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PIEZO-101.